Triptolide-induced cuproptosis is a novel antitumor strategy for the treatment of cervical cancer

Background: Cuproptosis is a unique copper-dependent form of cell death that is highly correlated with the metabolic state of cells. Triptolide exerts pharmacological activity by altering the regulation of metal ions. Cuproptosis is poorly understood in Cancer, so in this study, we explored whether triptolide could induce Cuproptosis in cervical Cancer cells.

Methods: The human cervical Cancer cell lines HeLa and SiHa, which primarily rely on Oxidative Phosphorylation, were treated with triptolide. Cell viability, proliferation and migration, copper levels and cuproptosis-related protein levels were evaluated in these cell lines. The copper ion chelator tetrathiomolybdate (TTM) was administered to determine whether it could reverse the Cuproptosis induced by triptolide. In addition, a nude mouse cervical Cancer xenograft model was established to determine the effects of triptolide on Cuproptosis in isolated tumor tissues.

Results: The copper concentration increased with triptolide treatment. The levels of Cuproptosis -related proteins, such as FDX1, LIAS, and DLAT, in the HeLa and SiHa cell lines decreased with triptolide treatment. XIAP, the target of triptolide, played a role in Cuproptosis by regulating COMMD1. The level of copper exporters (ATP7A/B) decreased, but the level of the copper importer (CTR1) did not change with triptolide treatment. Furthermore, triptolide inhibited cervical Cancer growth and induced Cuproptosis in vivo.

Conclusions: In summary, we report a new antitumor mechanism by which triptolide disrupted intracellular copper homeostasis and induced Cuproptosis in cervical Cancer by regulating the XIAP/COMMD1/ATP7A/B axis.

COMMD1; Cervical cancer; Cuproptosis; Triptolide; XIAP.